I’ve established a direct line with the SEC’s
Post# of 157823
(Total Views: 569)
Posted On: 07/11/2025 11:46:46 AM
I’ve established a direct line with the SEC’s Office of Investor Education and Advocacy (OIEA) regarding ongoing concerns.
Our referral number is for us.
SEC Case ID: HO-01493392
This is logged, searchable, and active inside their system. Use that number if you call or email. I’ll give the number via DM.
If any shareholders want to submit additional information or raise concerns, the OIEA is the correct place. They route evidence internally and help guide investor disclosures.
Contact OIEA:
help@sec.gov
Email is the best for submitting evidence or even just concerns. Please don’t try FOIA anything as the investigation is already active.
Our referral number is for us.
SEC Case ID: HO-01493392
This is logged, searchable, and active inside their system. Use that number if you call or email. I’ll give the number via DM.
If any shareholders want to submit additional information or raise concerns, the OIEA is the correct place. They route evidence internally and help guide investor disclosures.
Contact OIEA:
help@sec.gov
Email is the best for submitting evidence or even just concerns. Please don’t try FOIA anything as the investigation is already active.
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36